Prexton therapeutics

Biotech & Life Sciences · Oss, Netherlands · Founded 2012

Prexton Therapeutics is dedicated to developing innovative drugs aimed at improving the quality of life for individuals suffering from brain disorders and other diseases. The company specializes in designing novel mGluR4 compounds, which are a new class of treatments for these conditions. Prexton Therapeutics primarily serves patients with neurological disorders, operating within the pharmaceutical and biotech market. The business model revolves around research and development of proprietary compounds, which are then licensed or sold to larger pharmaceutical companies for further development and commercialization. Revenue is generated through licensing agreements, milestone payments, and royalties from sales of the developed drugs. Keywords: mGluR4, brain disorders, neurological, innovative drugs, biotech, pharmaceutical, R&D, licensing, proprietary compounds, quality of life.

Valuation $1–2.5B

Headcount <100

Total funding $10–50M

Unlock exact values

Power Law Unicorn$1–10B valuation tier

Investors

7 investors on Prexton therapeutics's cap table

Sourced from Dealroom's funding history.

Seed 1 investor entered at this stage

Eclosion

Series A 4 investors entered at this stage

Ysios Capital

M Ventures

Seroba Life Sciences

Forbion Capital Partners

Series B+ 2 investors entered at this stage

Seroba Life Sciences

Forbion Capital Partners

Global footprint

Where Prexton therapeutics has talent and traffic

Workforce by country

🇳🇱 Netherlands · Oss HQ

Book a demo for the full country breakdown

Web traffic by country

1.1K monthly visits
across markets

🇺🇸 United States45.5%

🇲🇪 Montenegro18.2%

🇩🇪 Germany18.2%

🇧🇪 Belgium9.1%

Top 4 markets shown

Talent graph

The shape of Prexton therapeutics's talent

Dealroom maps Prexton therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

8 team members profilednamed & role-tagged by Dealroom

1 employeestotal headcount

3 executives & foundersidentified by name

DimensionScore

AI Talent

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Prexton therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$26k patent portfolio · 2 active families

Estimated portfolio value

$26k

<0.01% of valuation · 1620.9× smaller than top peer Voyager Therapeutics ($42M)

2 active patent families

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Prexton therapeutics

An AI-synthesized read of the highest-engagement posts about Prexton therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Prexton therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles